-97-
`
`Publications (Continued)
`
`314. Ruffolo, R.R., Jr.: Adrenocegtors: Structure, Function and Pharmacology. Edited by
`R.R. Ruffolo, Jr., Harwood Academic Press, London, pp. 1—287, 1995.
`
`315. Douglas, S.A., Vickery—Clark, L.M., Louden, C., Ruffolo, R.R., Jr., Feuerstein, G2.
`and Ohlstein, E.O.: Acute pretreatment with carvedilol is sufficient for inhibition
`of neointima formation following rat carotid artery balloon angioplasty.
`Pharmacol. Communications 5: 65—72, 1994.
`
`316. Autieri, M.V., Feuerstein, G.Z., Yue, T.L., Ruffolo, R.R., Jr., Ohlstein, E.H. and
`Douglas, S.A.: Differential gene expression associated with neointima
`formation induced by carotid artery balloon angioplasty in the rat. Circ. Res.,
`submitted.
`
`317.
`
`318.
`
`319.
`
`Feuerstein, G2. and Ruffolo, R.R., Jr.: Comparison of the ability of two vasodilating,
`B-blockers, carvedilol and celiprolol, to reduce infarct size in a pig model of
`acute myocardial infarction. Pharmacol. Communications 5: 57—63, 1994.
`
`Feuerstein, G.Z., Yue, T.-L. and Ruffolo, R.R., Jr.: Carvedilol Update: A multiple
`action antihypertensive agent with antioxidant activity and the potential for
`myocardial and vascular protection (Japanese Translation). Drugs of Today @
`(Suppl. 1): 1-20, 1994.
`
`Bril, A., Faivre, J.F., Forest, M.C., Cheval, B., Gout, B., Linee, Ph., Ruffolo, R.R., Jr.
`and Poyser, R.H.: Electrophysiological characteristics of BRL 32872, a novel
`antiarrhythmic agent with potassium and calcium channel blocking properties,
`in guinea pig cardiac isolated preparations. J. Pharmacol. Exp. Ther. fl:
`1264-1272, 1995.
`
`320. Ruffolo, R.R., Jr. and Poste, G.: A prescription for better prescriptions: A response.
`Issues in Science and Technology, Summer Supplement, page 9, 1994.
`
`321.
`
`Feuerstein, G2. and Ruffolo, R.R., Jr.: The antiplatelet GPllb/llla antibody, 7E3: A
`pioneer drug for the treatment of arterial thrombotic disorders. Expert Opinions
`in lnvestigational Drugs 3: 745—752, 1994.
`
`322. Wang, X., Yue, T.-L., Barone, F.C., Ruffolo, R.R., Jr. and Feuerstein, G.Z.:
`Differential display of gene expression in rat focal brain ischemia.
`Neuroscience Protocols 95-020—02: 1-9, 1995.
`
`323. The Contributors (Ruffolo, R.R., Jr. and 36 Other Contributors). The RBI Handbook of
`Receptor Classification. Edited by J.W. Kebabian and J.L. Neumeyer,
`Research Biochemicals International, Natick, 1994.
`
`324. Ruffolo, R.R., Jr. and Hollinger, M.: G—Protein Cougled Transmembrane Signaling
`Mechanisms, edited by R.R. Ruffolo, Jr. and M. Hollinger, CRC Press, Boca
`Raton, pp. 1—204, 1995.
`
`P-97
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`lPR2020-00769
`
`United Therapeutics EX2006
`Page 4165 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4165 of 7113
`
`

`

`-98-
`
`Publications (Continued)
`
`325.
`
`326.
`
`327.
`
`328.
`
`329.
`
`330.
`
`331.
`
`332.
`
`333.
`
`334.
`
`Li, Y—O., Hieble, J.P., Bergma, D.J., Swift, A.M., Ganguli, S. and Ruffolo, R.R., Jr.:
`The B—hydroxyl group of catecholamines may interact with Ser-q0 of the second
`transmembrane helix of the a2A-adrenoceptor. Pharmacol. Commun. 6: 125-
`131, 1995.
`
`Wang, X., Yue, T.—L., Barone, F.C., Ruffolo, R.R., Jr. and Feuerstein, G.Z.:
`Identification of novel gene expression induced by focal ischemia using mRNA
`differential display.
`In: Pharmacology of Cerebral Ischemia, J. Krieglstein and
`H. Oberpichler—Schwenk, Editors, pp. 473—478, 1994.
`
`Hieble, JP. and Ruffolo, R.R., Jr.: Possible structural and functional relationships
`between imidazoline receptors and a2—adrenoceptors. Ann. NY. Acad. Sci.
`E: 8-21, 1995.
`
`Ruffolo, R.R., Jr.: G-Protein Coupled Transmembrane Signaling Mechanisms;
`Preface.
`in: G—Protein Coupled Transmembrane Signaling Mechanisms,
`edited by R.R. Ruffolo, Jr. and M. Hollinger. CRC Press, Boca Raton, pp. i-iii,
`1995.
`
`Bylund, D.B., Regan, J.W., Faber, J.E., Hieble, J.P., Triggle, C. and Ruffolo, R.R., Jr.:
`Vascular oc—adrenoceptors: From the gene to the human. Can. J. Physiol.
`Pharmacol. 3: 533—543, 1995.
`
`Testa, R., Taddei, C., Poggesi, E., Destefani, C., Cotecchia, S., Hieble, J.P., Sulpizio,
`A.C., Naselsky, D., Bergsma, D., Ellis, C., Swift, A., Ganguly, S., Ruffolo, R.R.,
`Jr. and Leonardi, A.: REC 15/2739 (SB 216469): A novel prostate selective
`om—adrenoceptor antagonist. Pharmacol. Commun. §: 79—86, 1995.
`
`Ruffolo, R.R., Jr. and Hieble, JP: The Adrenoceptors: Historical perspectives,
`current status and future directions. Pharmacol. Commun. 6: 1-7, 1995.
`
`Yue, T.L., Wang, X., Gu, J.L., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Carvedilol: A
`new vasodilating B-adrenoceptor blocker, inhibits oxidation of low density
`lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion
`to smooth muscle cells. J. Pharmacol. Exp. Ther. E: 1442-1449, 1995.
`
`Hieble, J.P., Ruffolo, R.R., Jr., Sulpizio, A.C., Naselsky, D.P., Conway, T.M., Ellis, 0.,
`Swift, A.M., Ganguly, S. and Bergsma, D.J.: Functional subclassification of a2-
`adrenoceptors. Pharmacol. Commun. g: 91—97, 1995.
`
`Li, Y—O., Hieble, J.P., Bergma, D.J., Swift, A.M., Ganguli, S. and Ruffolo, R.R., Jr.:
`The B—hydroxyl group of catecholamines may interact with Ser90 of the second
`transmembrane helix of the a2A-adrenoceptor.
`In: Adrenoceptors: Structure
`Function and Pharmacology, edited by R.R. Ruffolo, Jr., Harwood Academic
`Publishers, Reading, pp. 125-131, 1995.
`
`P-98
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`lPR2020-00769
`
`United Therapeutics EX2006
`Page 4166 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4166 of 7113
`
`

`

`-99-
`
`Publications (Continued)
`
`335.
`
`336.
`
`337.
`
`338.
`
`339.
`
`340.
`
`341.
`
`342.
`
`343.
`
`344.
`
`Testa, R., Taddei, C., Poggesi, E., Destefani, C., Cotecchia, 3., Hieble, J.P., Sulpizio,
`A.C., Naselsky, D., Bergsma, D., Ellis, 0., Swift, A., Ganguly, S., Ruffolo, R.R.,
`Jr. and Leonardi, A.: REC 15/2739 (SB 216469): A novel prostate selective
`a1—adrenoceptor antagonist.
`In: Adrenoceptors: Structure Function and
`Pharmacology, edited by R.R. Ruffolo, Jr., Harwood Academic Publishers,
`Reading, pp. 79—86, 1995.
`
`Ruffolo, R.R., Jr. and Hieble, JP: The Adrenoceptors: Historical perspectives,
`current status and future directions.
`In: Adrenoceptors: Structure, Function
`and Pharmacology, edited by R.R. Ruffolo, Jr., Harwood Academic Publishers,
`Reading, pp. 1—7, 1995.
`
`Hieble, J.P., Ruffolo, R.R., Jr., Sulpizio, A.C., Naselsky, D.P., Conway, T.M., Ellis, C.,
`Swift, A.M., Ganguly, S. and Bergsma, D.J.: Functional subclassification of a2—
`adrenoceptors.
`In: Adrenoceptors: Structure, Function and Pharmacology,
`edited by R.R. Ruffolo, Jr., Harwood Academic Publishers, Reading, pp. 91—97,
`1995.
`
`Christopher, T.A., Yue, T.—L., Feuerstein, G.Z., Ruffolo, R.R., Jr., Lopez, BL and Ma,
`X-L.: Carvedilol, a new B-adrenoceptor blocker, vasodilator and free radical
`scavenger, exerts an anti—shock and endothelial protective effect in rat
`splanchnic ischemia and reperfusion. J. Pharmacol. Exp. Ther. fl: 64—71,
`1995.
`
`Hieble, J.P., McCafferty, G.P., Naselsky, D.P., Bergsma, DJ and Ruffolo, R.R., Jr.:
`Recent progress in the pharmacotherapy of diseases of the lower urinary tract.
`European Journal of Medicinal Chemistry, Proceedings of the Xlllth
`International Symposium on Medicinal Chemistry, edited by JG. Muller, pp.
`2705—2985, 1995.
`
`Feuerstein, G2. and Ruffolo, R.R., Jr.: Ticlopidine: A novel antiplatelet drug for
`prevention of thrombotic disorders. Expert Opinion in Investigational Drugs g:
`1163-1169, 1994.
`
`Hieble, JP. and Ruffolo, R.R., Jr.: Subclassification of the B-adrenoceptors.
`Pharmacol. Commun. Q: 183-193, 1995.
`
`Introduction. Adrenoceptors: Structure, Function and
`Ruffolo, R.R., Jr.:
`Pharmacology. Pharmacol. Commun., page v, Volume 6 (No. 1—3), 1995.
`
`Ruffolo, R.R., Jr.: Adrenoceptors: Structure, Function and Pharmacology; Preface.
`In: Adrenoceptors: Structure, Function and Pharmacology, edited by R.R.
`Ruffolo, Jr., Harwood Academic Publishers, Reading, pp. vii-ix, 1995.
`
`In:
`Hieble, JP. and Ruffolo, R.R., Jr.: Subclassification of the B-adrenoceptors.
`Adrenoceptors: Structure Function and Pharmacology, edited by R.R. Ruffolo,
`Jr., Harwood Academic Publishers, Reading, pp. 183—193, 1995.
`
`P-99
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4167 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4167 of 7113
`
`

`

`-100-
`
`Publications (Continued)
`
`345.
`
`346.
`
`347.
`
`348.
`
`349.
`
`350.
`
`351.
`
`352.
`
`353.
`
`354.
`
`355.
`
`356.
`
`Hieble, J.P., Bylund, D.B., Clarke, D.E., Eikenberg, D.C., Langer, S.Z., Lefkowitz,
`R.J., Minneman, K.P. and Ruffolo, R.R., Jr.:
`International Union of
`Pharmacology Nomenclature of Adrenoceptors. Recommendation for
`Nomenclature of a1—adrenoceptors: Consensus Update. Pharmacol. Rev. fl:
`267-270, 1995.
`
`In:
`Inflammation: Mediators and Pathways; Preface.
`Ruffolo, R.R., Jr.:
`Inflammation: Mediators and Pathways, edited by R.R. Ruffolo, Jr. and M.
`Hollinger, CRC Press, Boca Raton, pp. i—iii, 1995.
`
`Lysko, P.G., Feuerstein, G.Z. and Ruffolo, R.R., Jr.: Carvedilol: A novel multiple
`action antihypertensive drug with multiple organ protective actions.
`Pharmaceutical News 2: 12-16, 1995.
`
`Ruffolo, R.R., Jr., Bondinell, W., Ku, T., Naselsky, DP. and Hieble, J.P.: a1-
`Adrenoceptors: Pharmacological classification and newer therapeutic
`applications. Proc. West. Pharmacol. Soc. E: 121—126, 1995.
`
`Feuerstein, G.Z. and Ruffolo, R.R., Jr.: Vascular restenosis: a disease in search of
`therapy. Expert Opinion in Investigational Drugs 4(3): 237-242, 1995.
`
`Ruffolo, R.R., Jr.: Cardiovascular Drugs: Past, Present and Future. Pharmaceutical
`News 2(2): 13-15, 1995.
`
`Yue, T-L., Gu, J-L., Lysko, P.M., Sponer, G., Cheng, H.Y., Ruffolo, R.R., Jr. and
`Feuerstein, G.Z.: Antioxidant activity of a B—adrenoceptor antagonist,
`Carazolol: Comparison with Propranolol and Carvedilol. Pharmacol. Commun.
`Z: 11-19, 1995.
`
`Feuerstein, G.Z., Poste, GP. and Ruffolo, R.R., Jr.: Carvedilol Update III. Rationale
`for Use in Congestive Heart Failure. Drugs of Today fl: 307—326, 1995.
`
`Feuerstein, G.Z., Nichols, A.J. and Ruffolo, R.R., Jr.: Clopidogrel: A novel
`antiplatelet drug for prevention and treatment of thrombotic disorders. Expert
`Opinion on Investigational New Drugs 4: 425-430, 1995.
`
`Bril, A., Gout, B., Bonhomme, M., Landais, L., Faiure, J.F., Linee, P., Poyser, RP.
`and Ruffolo, R.R., Jr.: Combined potassium and calcium channel blocking
`activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk:
`experimental profile of BRL 32872. J. Pharmacol. Exp. Ther., in press.
`
`Ruffolo, R.R., Jr.: Editor, Special Issue. Pharmacology of Adrenoceptors.
`Pharmacol. Comm, Volume 6, Numbers 1-3, pp. 1-279, 1995.
`
`Inflammation: Mediators and Pathways.
`Ruffolo, R.R., Jr. and Hollinger, M.A.:
`Edited by R.R. Ruffolo, Jr. and MA. Hollinger, CRC Press, Boca Raton, pp. 1—
`206, 1995.
`
`P100
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4168 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4168 of 7113
`
`

`

`-101-
`
`Publications (Continued)
`
`357. Yue, T.L., Wang, X., Gu, J.L., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Carvedilol
`prevents low-density lipoprotein (LDL)—enhanced monocyte adhesion to
`endothelial cells by inhibition of LDL oxidation. Eur. J. Pharmacol. &: 585-
`591, 1995.
`
`358. Ma, X.L., Yue, T.L., Lopez, B.L., Barone, F.C., Christopher, T.A., Ruffolo, R.R., Jr.
`and Feuerstein, G.Z.: Carvedilol, a new B—adrenoceptor blocker and free
`radical scavenger, attenuates myocardial ischemia-reperfusion injury in
`hypercholesterolemic rabbits. J. Pharmacol. Exp. Ther. E: 128—136, 1996.
`
`359. Ruffolo, R.R., Jr. and Feuerstein, G.Z.: The Pharmacology of Carvedilol: Rationale
`for use in hypertension, coronary artery disease and congestive heart failure.
`Cardiovasc. Drugs Ther. fl: 247-256, 1997.
`
`360. Hieble, JP. and Ruffolo, R.R., Jr.: Subclassification and nomenclature of a1- and a2-
`adrenoceptors.
`In: Progress in Drug Research, Volume 47, edited by E.
`Jucker, Birkhauser Verlag, Basel, pp. 81-130, 1996.
`
`361.
`
`Li, Y.—O., Hieble, J.P., Bergsma, D.J., Swift, A.M., Ganguly, S. and Ruffolo, R.R., Jr.:
`Identification of potential sites for interactions of catecholamines with the 0L2A-
`adrenoceptor by site—directed mutagenesis: The molecular basis for the
`Easson—Stedman Hypothesis. Submitted for publication.
`
`362. Ohlstein, E.H., Elliott, J.P., Feuerstein, G.Z., and Ruffolo, R.R., Jr.: Endothelin
`receptors: Receptor classification, novel receptor antagonists and potential
`therapeutic targets. Med. Res. Rev. E: 365—390, 1996.
`
`Identification, characterization and
`363. Hieble, J.P., Ruffolo, R.R., Jr. and Starke, K.
`subclassification of ocz—adrenoceptors: An overview.
`In: gz—Adrenergic
`Receptors: Structure Function and Therapeutic Implications, Edited by SM.
`Lanier and L. Limbird, Harwood Academic Publishers, Reading, pp. 1—18—,
`1996.
`
`364.
`
`365.
`
`366.
`
`Feuerstein, G.Z., Fisher, M., Nunnari, M. and Ruffolo, R.R., Jr.: Carvedilol inhibits
`aortic lipid deposition in the hypercholesterolemic rat. Pharmacology E: 24-
`32, 1997.
`
`Lukas, M.A., Ruffolo, R.R., Jr., Shusterman, N.H., Sponer, G. and Strein, K.: Method
`of treatment for decreasing mortality resulting from congestive heart failure.
`United States Patent #5,760,069, June 2, 1998.
`
`Lopez, B.L., Christopher, T.A., Yue, T.L., Ruffolo, R.R., Jr., Feuerstein, 6.2. and Ma,
`X.L. Carvedilol, a new B-adrenoceptor blocker antihypertensive drug, protects
`against free—radical—induced endothelial dysfunction. Pharmacology Q: 165—
`173, 1995.
`
`P101
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`lPR2020-00769
`
`United Therapeutics EX2006
`Page 4169 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4169 of 7113
`
`

`

`-102-
`
`Publications (Continued)
`
`367.
`
`368.
`
`369.
`
`370.
`
`371.
`
`372.
`
`373.
`
`374.
`
`375.
`
`376.
`
`Hieble, J.P., Hehr, A., Li, Y—O., Naselsky, DP. and Ruffolo, R.R., Jr.:
`Characterization of stereoselective interactions of catecholamines with the
`
`age-adrenoceptor vi_a site-directed mutagenesis. In: g2-Adrenergic Receptors:
`Structure Function and Therapeutic Implications, Edited by SM. Lanier and L.
`Limbird, Harwood Academic Publishers, Reading, pp. 43-51, 1996.
`
`Feuerstein, G.Z, and Ruffolo, R.R., Jr.: Carvedilol: Preclinical profile and rationale for
`its use in hypertension, coronary syndromes and congestive heart failure.
`Cardiovascular Reviews and Reports fl: 27—38, 1996.
`
`Wang, X., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: mRNA Differential Display: A new
`technology for discovery of novel pharmacological targets. Trends Pharmacol.
`Sci. fl: 276-279, 1996.
`
`Wang, X., Yue, T-L., Barone, PC, White, R.F., Clark, R.K., Willette, R.N., Sulpizio,
`A.C., Aiyar, N.V., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Discovery of
`adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating
`focal brain ischemic damage. Proc. Natl. Acad. Sci. Q: 11480-11484, 1995.
`
`Hieble, JP. and Ruffolo, R.R., Jr.: The use of oc-adrenoceptor antagonists in the
`pharmacological management of benign prostatic hypertrophy: an overview.
`Pharmacol. Res. Q: 145—160, 1996.
`
`Feuerstein, G.Z. and Ruffolo, R.R., Jr.: Gene therapy for restenosis: status, issues
`and future directions.
`In: Coronary Restenosis: From Genetics and
`Therapeutics, edited by G.Z. Feuerstein, Marcel Decker, New York, pp. 455—
`468, 1996.
`
`Hehr, A., Hieble, J.P., Li, Y—O., Bergsma, D.J., Swift, A.M., Ganguly, S. and Ruffolo,
`R.R., Jr.: Serine165 of transmembrane helix IV is not involved in the interaction
`of catecholamines with the oczA—adrenoceptor. Pharmacology $18—24, 1997.
`
`Hieble, J.P., Naselsky, D.P., Arch, J.R.S., Chapman, H., Smith, S.A., Poyser, RH.
`and Ruffolo, R.R., Jr.: Affinity of carvedilol for recombinant human
`adrenoceptors. Pharmacol. Rev. Commun. fl: 43-50, 1998.
`
`Ruffolo, R.R., Jr., Trendelenburg, U. and Langer, 8.2.: Chemical Neurotransmission:
`Peripheral Autonomic Nervous System.
`In: Principles of Pharmacology.
`Edited by PL. Munson, R.A. Mueller and GR. Breese, Chapman and Hall,
`New York,
`in press.
`
`Feuerstein, G.Z., Bril, A. and Ruffolo, R.R., Jr.: Sotalol and d—Sotalol: Apparent
`benefits of B-blocking activity for ventricular arrhythmias. Expert Opinion on
`Investigational Drugs Q: 575—580, 1996.
`
`P102
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`lPR2020-00769
`
`United Therapeutics EX2006
`Page 4170 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4170 of 7113
`
`

`

`-103-
`
`Publications (Continued)
`
`377.
`
`378.
`
`379.
`
`380.
`
`381.
`
`382.
`
`383.
`
`384.
`
`385.
`
`In:
`Hieble, JP. and Ruffolo, R.R., Jr.: Adrenergic pharmacology of carvedilol.
`Carvedilol: A Multiple Action Neurohormonal Antagonist. Edited by R.R.
`Ruffolo, Jr., G. Poste and C. Sohn, Harwood Academic Publishers, London, in
`press.
`
`Gellai, M., Brooks, D.P., Bril, A. and Ruffolo, R.R., Jr.: Hemodynamic effects of
`carvedilol. In: Carvedilol: A Multiple Action Neurohormonal Antagonist. Edited
`by R.R. Ruffolo, Jr., G. Poste and C. Sohn, Harwood Academic Publishers,
`London, in press.
`
`Feuerstein, G.Z., Yue, T—L. and Ruffolo, R.R., Jr.: Antioxidant activity of carvedilol. In:
`Carvedilol: A Multiple Action Neurohormonal Antagonist. Edited by R.R.
`Ruffolo, Jr., G. Poste and C. Sohn, Harwood Academic Publishers, London, in
`press.
`
`Feuerstein, G.Z., Bril, A., Ohlstein, E.H., Brooks, DP. and Ruffolo, R.R., Jr.: Major
`organ protection by carvedilol (heart/cardioprotection, kidneys/ renoprotection,
`de-emphasis blood vessels/remodeling, brain).
`In: Carvedilol: A Multiple
`Action Neurohormonal Antagonist. Edited by R.R. Ruffolo, Jr., G. Poste and C.
`Sohn, Hanivood Academic Publishers, London, in press.
`
`Feuerstein, G.Z., Ohlstein, E.H., Poste, G., Ma, X, Yue, T—L., Ruffolo, R.R., Jr.:
`Apoptosis, adhesion molecules, endothelial function, foam cells, gene
`expression — Additional actions of carvedilol.
`In: Carvedilol: A Multiple Action
`Neurohormonal Antagonist. Edited by R.R. Ruffolo, Jr., G. Poste and C. Sohn,
`Harwood Academic Publishers, London, in press.
`
`Feuerstein, G.Z., Yue, T-L. and Ruffolo, R.R., Jr.: Emerging concepts in heart failure:
`Apoptosis in CHF.
`In: Carvedilol: A Multiple Action Neurohormonal
`Antagonist. Edited by R.R. Ruffolo, Jr., G. Poste and C. Sohn, Harwood
`Academic Publishers, London, in press.
`
`Introduction: Rationale for
`Ruffolo, R.R., Jr., Feuerstein, G.Z., Poste, G. and Ma, X.:
`use of carvedilol in hypertension, coronary artery disease and congestive heart
`failure.
`In: Carvedilol: AMultiple Action Neurohormonal Antagonist. Edited by
`R.R. Ruffolo, Jr., G. Poste and C. Sohn, Harwood Academic Publishers,
`London, in press.
`
`Feuerstein, G.Z., Shusterman, N.H., Poste, G. and Ruffolo, R.R., Jr.: B—Blockers and
`heart failure: Rationale and highlights fro the Carvedilol Heart Failure Trials.
`Drug News and Perspectives 3: 18—22, 1996.
`
`Ruffolo, R.R., Jr.: Carvedilol: an a- and B-adrenoceptor antagonist that inhibits LDL
`oxidation. Proceedings from the International Symposium on Lipoprotein
`Oxidation and Atherosclerosis: Biological and Clinical Aspects, edited by G.
`Finardi, G. Bellomo and E. Maggi, Richelieu Press, pp. 19—23, 1996.
`
`P403
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4171 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4171 of 7113
`
`

`

`—1 04—
`
`Publications (Continued)
`
`386.
`
`387.
`
`388.
`
`389.
`
`390.
`
`391.
`
`392.
`
`393.
`
`394.
`
`395.
`
`396.
`
`Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Carvedilol: Preclinical profile and
`mechanisms of action in preventing the progression of congestive heart failure.
`Eur. Heart J. 3 (Suppl. B): B19-B24, 1998.
`
`Hieble, JP. and Ruffolo, R.R., Jr.: Experimental and emerging drugs: 0(-
`Adrenoceptor Agonists and Antagonists.
`In: Receptor—Based Drug Design,
`edited by P. Leff, Marcel Dekker, New York, pp. 231—252, 1998.
`
`Ruffolo, R.R., Jr.: The role of 0L— and B—adrenoceptors in cardiovascular diseases:
`Recent developments.
`In: Proceedings of Euro-Conference Symposium on
`the Role of Drug Receptors in Cardiovascular Disease. Edited by B. Verstig,
`1996.
`
`Bril, A., Feuerstein, G.Z. and Ruffolo, R.R., Jr.: Carvedilol, a new paradigm for the
`treatment of congestive heart failure. Expert Opinion on Investigational Drugs
`Q: 1523—1529, 1996.
`
`Feuerstein, G. and Ruffolo, R.R., Jr.: B-Blockers in congestive heart failure. The
`pharmacology of carvedilol, a vasodilating B—blocker and antioxidant and its
`therapeutic utility in congestive heart failure.
`In: Catecholamines Bridging
`Basic Science with Clinical Medicine. Edited by US Goldstein, G. Eisenhofer
`and R. McCarthy, Academic Press, London. Adv. Pharmacol. Q: 611—615,
`1998.
`
`Feuerstein, G.Z., Poste, G., Shusterman, NH. and Ruffolo, R.R., Jr.: The changing
`paradigm for pharmacotherapy of congestive heart failure. Cardiovasc. Drugs
`Ther. 11: 98-148, 1998.
`
`Ruffolo, R.R., Jr., Feuerstein, G.Z. and Ohlstein, E.H.: Recent observations with [3—
`adrenoceptor blockade: Beneficial effects in hypertension and heart failure.
`Am. J. Hypertension 11 (Suppl.):9S—14S, 1998.
`
`Hieble, JP. and Ruffolo, R.R., Jr.: Pharmacotherapy of benign prostatic hypertrophy
`with ocq—adrenoceptor agonists. Pharmacol. Rev. Commun. 8:251—256, 1996.
`
`Feuerstein, G.Z., Ruffolo, R.R., Jr. and Samanen, J.: The integrin all [33 (GPIIb/Illa).
`Atarget for novel antiplatelet drugs. Pharmacol. Rev. Commun. §: 257—265,
`1996.
`
`Hieble, JP. and Ruffolo, R.R., Jr.: Recent advances in the identification of (11- and
`ocz—adrenoceptor subtypes: Therapeutic implications. Expert Opinion on
`Investigational Drugs §: 367—387, 1997.
`
`Feuerstein, G.Z., Bril, A. and Ruffolo, R.R., Jr.: Pharmacology of B—Blockers:
`Protective effects of carvedilol in the myocardium. Am. J. Cardiol. 80(11A1;
`41L—45L, 1997.
`
`P104
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4172 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4172 of 7113
`
`

`

`-105-
`
`Publications (Continued)
`
`397.
`
`398.
`
`399.
`
`400.
`
`401.
`
`402.
`
`403.
`
`404.
`
`405.
`
`406.
`
`407.
`
`Feuerstein, G.Z., Ruffolo, R.R., Jr. and Yue, T—L.: Apoptosis and congestive heart
`failure. Cardiovascular Medicine Z: 249—255, 1997.
`
`Feuerstein, G.Z., Shusterman, N., Ruffolo, R.R., Jr.: Carvedilol Update IV:
`Prevention of oxidative stress, cardiac remodeling and progression of
`congestive heart failure. Drugs of Today Q: 453—473, 1997.
`
`Ruffolo, R.R., Jr.: Pharmacology of B-adrenoceptor blockade. Perspectives in
`Cardiology (Supplement, August 1997); Proceedings of the International
`Meeting of the Canadian Cardiac Society Symposium on Evolution of Heart
`Failure Management: Emerging role of B—blockers, pp. 11—14, 1997.
`
`Ma, X.L., Lopez, B.L., Liu, G.L., Christopher, T.A., Gao, F., Guo, Y., Feuerstein, G.Z.,
`Ruffolo, R.R., Jr., Barone, FC and Yue, T.L.: Hypercholesterolemia impairs a
`detoxification mechanism against peroxynitrite and renders the vascular tissue
`more susceptible to oxidative injury. Circ. Res. @: 894—901, 1997.
`
`Feuerstein, G2. and Ruffolo, R.R., Jr.: The Pharmacology of Carvedilol. Trends
`Pharmacol. Sci, in press.
`
`Gurbanov, K., Callanan, E., Feuerstein, G.Z., Ruffolo, R.R., Jr., Brodski, S., Hoffman,
`A., Haramati, A. and Winaver, J.: Effects of carvedilol on renal function in rats
`with experimental congestive heart failure.
`International J. Science Medicine,
`2005.
`
`Griswold, D., Ruffolo, R.R., Jr., Poste, G. and Torphy, T.J.: Prostaglandin H2
`synthase isoforms and their relationship to gastrointestinal side effects. Trends
`in Pharmacol. Sci. fl: 311-313, 1997.
`
`Yue, T-L., Ma, X-L., Wang, X., Romanic, A.M., Liu, G-L., Londen, C., Gu, J-L., Kumar,
`S., Poste, G., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Possible involvement of
`the stress—activated protein kinase signaling pathway and Fas receptor
`expression in prevention of ischemia/reperfusion induced cardiomyocyte
`apoptosis by carvedilol. Circ. Res. Q: 166—174, 1998.
`
`In: E
`Ruffolo, R.R., Jr., Poste, GP. and Metcalf, B.W.: Preface to the Series.
`Cycle Regulation. Edited by R. Ruffolo, Jr., G. Poste and B. Metcalf, Harwood
`Academic Publishers, London, pp. xi-xii, 1997.
`
`In: Cell Cycle
`Ruffolo, R.R., Jr., Poste, G. and Metcalf, B.W.: Preface to the Volume.
`Regulation. Edited by R. Ruffolo, Jr., G. Poste and B. Metcalf, Harwood
`Academic Publishers, London, pp. xiii—xiv, 1997.
`
`Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Neurohormonal activation, oxygen free
`radicals and apoptosis in the pathogenesis of congestive heart failure. J.
`Cardiovasc. Pharmacol. 32 (Suppl. 1): 822—830, 1998.
`
`P105
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4173 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4173 of 7113
`
`

`

`-106-
`
`Publications (Continued)
`
`408.
`
`409.
`
`410.
`
`411.
`
`412.
`
`413.
`
`414.
`
`415.
`
`416.
`
`417.
`
`Inhibition of
`Ohlstein, E.H., Brooks, D.P., Feuerstein, G.Z. and Ruffolo, R.R., Jr.:
`sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but
`not by losartan, valsartan and irbesartan: Possible relationship to differences
`in prejunctional angiotensin II receptor blockade. Pharmacology fl: 244—251,
`1997.
`
`Feuerstein, G.Z. and Ruffolo, R.R., Jr.: Congestive Heart Failure and genomic
`medicine: A look into the 21st Century. Cardiovasc. Drugs Ther. fl: 713-717,
`1997.
`
`Willette, R.N., Mitchell, M.P., Ohlstein, E.H., Lukas, MA. and Ruffolo, R.R., Jr.:
`Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in
`rat heart. Pharmacology E: 30-36, 1998.
`
`Ruffolo, R.R., Jr., Poste, G. and Metoalf, B.W. Cell Cycle Regulation. Edited by R.R.
`Ruffolo, Jr., G. Poste and B.W. Metoalf, Harwood Academic Publishers,
`London, pp. 1—174, 1997.
`
`Feuerstein, G.Z., Liu, G.L., Yue, T.L., Cheng, H.Y., Hieble, J.P., Arch, J., Ruffolo,
`R.R., Jr. and Ma, X.L.: Comparison of metoprolol and carvedilol pharmacology
`and cardioprotection in rabbit ischemia and reperfusion model. Proceedings
`from the Xlllth World Congress of Cardiology, Monduzzi Editore S.p.A.,
`Bologna, Italy, pp. 959-963, 1998.
`
`Yue, T.L., Ma, X.L., Gu, J.L., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Carvedilol
`inhibits activation of stress—activated protein kinase and reduces reperfusion
`injury in perfused rabbit heart. Eur. J. Pharmacol. fl: 61—65, 1998.
`
`Brodsky, S., Gurbanov, K., Abassi, Z., Hoffman, A., Ruffolo, R.R., Jr., Feuerstein,
`G.Z. and Winaver, J.: Effect of eprosartan on renal function and cardiac
`hypertrophy in rats with experimental heart failure. Hypertension Q: 746—752,
`1998.
`
`Gellai, M., Schreiner, G.T., Ruffolo, R.R., Jr., Fletcher, T., DeWoIf, R. and Brooks,
`D.P.: CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic
`activities. J. Pharmacol. Exp. Ther. &: 1191-1196, 1998.
`
`Brunvand, H., Liu, G., Ma, X.L., Yue, T.L., Ruffolo, R.R., Jr. and Feuerstein, G.Z.: SB
`211475, a metabolite of carvedilol, reduces infarct size after myocardial
`ischemic and reperfusion injury in rabbits. Eur. J. Pharmacol. fl: 193-198,
`1998.
`
`Inflammatory cells and mediators in
`Ruffolo, R.R., Jr., Poste, G. and Metoalf, B.W.:
`central nervous system diseases; Preface to the Series.
`In:
`Inflammatory
`Cells and Mediators in Central Nervous System Diseases. Edited by R.R.
`Ruffolo, Jr., G. Poste and B.W. Metoalf, Harwood Academic Publishers,
`London, pp. XI—XII, 1999.
`
`P106
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4174 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4174 of 7113
`
`

`

`-107-
`
`Publications (Continued)
`
`418.
`
`419.
`
`420.
`
`421.
`
`422.
`
`423.
`
`424.
`
`425.
`
`426.
`
`427.
`
`428.
`
`Edwards, R.M., Ruffolo, R.R., Jr. and Brooks, D.P.: Pharmacology of the angiotensin
`II receptor antagonist, eprosartan. Expert Opinion on lnvestigational Drugs Z:
`463-489, 1998.
`
`Christopher, T.A., Lopez, B.L., Ma, X.L., Feuerstein, G.Z., Ruffolo, R.R., Jr. and Yue,
`T.L.: Effects of a hydroxylated metabolite of the B—adrenoceptor antagonist,
`carvedilol, on post—ischemic splanchnic tissue injury. Br. J. Pharmacol. fl:
`292-298, 1998.
`
`Ruffolo, R.R., Jr.: Pharmacology of Carvedilol. Proceedings of the Canadian Cardiac
`Society Symposium on Congestive Heart Failure. New Advances in the
`Treatment of Congestive Heart Failure, pp. 9—10, 1998.
`
`Humphrey, P.P.A. and Ruffolo, R.R., Jr.: The IUPHAR Compendium on Receptor
`Characterization and Classification: Preface.
`In: The IUPHAR Compendium
`of Receptor Characterization and Classification. Edited by P. Godfraind, P.M.
`Vanhoutte, R.R. Ruffolo, Jr. and P. Humphrey, IUPHAR Media, Burlington
`Press, Cambridge, pp. vii, 1998.
`
`Hieble, J.P., Hehr, A., Li, Y0. and Ruffolo, R.R., Jr.: Molecular basis for the
`stereoselective interactions of catecholamines with oc—adrenoceptors. Proc.
`West. Pharmacol. Soc. fl: 225—228, 1998.
`
`Godfraind, T., Vanhoutte, P.M., Ruffolo, R.R., Jr. and Humphrey, P.: The IUPHAR
`Compendium of Receptor Characterization and Classification.
`IUPHAR Media,
`Burlington Press, Cambridge, 267 pages, 1998.
`
`Hieble, J.P., Kolpak, D.C., McCafferty, G.P., Ruffolo, R.R., Jr., Testa, R. and
`Leonardi, A.: Effects of a1 —adrenoceptor antagonists on agonist and tilt—
`induced changes in blood pressure: relationships to uroselectivity. Eur. J.
`Pharmacol. fl: 51—82, 1999.
`
`Feuerstein, G.Z., Yue, TL. and Ruffolo, R.R., Jr.: Novel mechanisms in the treatment
`of heart failure:
`Inhibition of oxygen radicals and apoptosis by carvedilol. Prog.
`Cardiovasc. Dis. fl(Suppl. 1), 17-24, 1998.
`
`Gurbanov, K.G., Chandra, S., Schaffer, T., Freed, T., Sarkar, S.K., Ohlstein, E.H.,
`Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Use of serial cardiac-gated magnetic
`resonance imaging for analysis of cardiac function and structure in
`experimental congestive heart failure: studies with carvedilol.
`In press.
`
`Brooks, D.P., Feuerstein, G.Z., Ohlstein, E0. and Ruffolo, R.R., Jr.: Method for
`treating isolated systolic hypertension. United States Patent, P50667. 9.13.99.
`
`Jobe, P.C., Adams-Curtis, L., Burks, T.F., Fuller, R.W., Peck, C.C., Ruffolo, R.R.,
`Snead, O.C., Woosley, R.L.: The essential role of integrative biomedical
`sciences in protecting and contributing to the Health and Well Being of our
`Nation. The Pharmacologistfl: 32-37, 1998.
`
`P107
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`IPR2020-00769
`
`United Therapeutics EX2006
`Page 4175 of 7113
`
`IPR2020-00769
`United Therapeutics EX2006
`Page 4175 of 7113
`
`

`

`-108-
`
`Publications (Continued)
`
`429.
`
`430.
`
`431.
`
`432.
`
`433.
`
`434.
`
`435.
`
`436.
`
`437.
`
`438.
`
`Brodsky, S., Gurbanov, K., Abassi, Z., Hoffman, A., Ruffolo, R.R., Jr., Feuerstein,
`G2. and Winaver, J.: Effects of eprosartan on renal function and cardiac
`hypertrophy in rats with experimental heart failure. Hypertension 2: 746-752,
`1998.
`
`Ruffolo, R.R., Jr. and Hieble, J.P.: Adrenoceptor Pharmacology: Urogenital
`Applications. Eur. Urologyfi (Suppl. 1): 17—22, 1999.
`
`Brooks, DP. and Ruffolo, R.R., Jr.: Pharmacological mechanisms of angiotensin II
`receptor antagonists:
`implication for the treatment of elevated systolic blood
`pressure.
`J. Hypertension fl (Suppl. 2): 827—832, 1999.
`
`Bylund, D.B., Bond, R.P., Clarke, D.E., Eikenburg, D.C., Hieble, J.P., Langer, S.Z.,
`Lefkowitz, R.J., Minneman, K.P., Molinoff, P.B., Ruffolo, R.R., Strosberg, AD.
`and Trendelenburg, U.G.: Adrenoceptors.
`In: The lUPHAR Compendium of
`Receptor Characterization and Classification. Edited by T. Godfraind, PM.
`Vanhoutte, R.R. Ruffolo, Jr. and P. Humphrey. Published by lUPHAR Media,
`Burlington Press, Cambridge, pp. 58-74, 1998.
`
`Douglas, S.A., Nambi, P., Gellai, M, Luengo, J.I., Xiang, J.N., Brooks, D.P., Ruffolo,
`R.R., Jr., Elliott, JD. and Ohlstein, E.O.: Pharmacologic characterization of the
`novel, orally available endothelin—A—selective antagonist, SB 247083. J.
`Cardiovasc. Pharmacol. fl: 8273-8276, 1998.
`
`Ruffolo, R.R., Jr. and Feuerstein, G.Z.: Recent developments in the use of beta-
`blockers in the treatment of heart failure. Pharmacol. and Toxicol. Q (Suppl.
`1): 42-43, 1998.
`
`Feuerstein, G., Liu, G.L., Yue, T.L., Cheng, H.Y., Hieble, J.P., Arch, J.R.S., Ruffolo,
`R.R., Jr. and Ma, X.L.: Comparison of metoprolol and carvedilol pharmacology
`and cardioprotection in rabbit ischemia and reperfusion model. Eur. J.
`Pharmacol. fl: 341—350, 1998.
`
`Feuerstein, G.Z., Shusterman, N.H., Poste, G. and Ruffolo, R.R., Jr.: The changing
`paradigm for pharmacotherapy of congestive heart failure.
`Internat. J.
`Cardiovasc. Med. Sci. fl: 171-189, 1998.
`
`Willette, R.N., Aiyar, N., Yue, T.L., Mitchell, M.P., Disa, J., Storer, B.L., Naselsky,
`D.P., Stadel, J.M., Ohlstein, E0. and Ruffolo, R.R., Jr.:
`|_nvit£and mm
`characterization of intrinsic sympathomimetic activity in normal and heart failure
`rats. J. Pharmacol. Exp. Ther. &: 48—53, 1999.
`
`Gubanov, K.G., Schaffer, C.S., Freed, T., Ruffolo, R.R., Jr., Sarkar, S.K., Ohlstein,
`E0. and Feuerstein, G.Z.: Utilization of Magnetic Resonance Imaging